Standout Papers

Lecanemab in ... 1997 2026 2006 2016 2.4k
  1. Lecanemab in Early Alzheimer’s Disease (2022)
    Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine
  2. The Amyloid-β Pathway in Alzheimer’s Disease (2021)
    Harald Hampel, John Hardy et al. Molecular Psychiatry
  3. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke (1997)
    Christopher Chen The Lancet
  4. Diagnostic Criteria for Vascular Cognitive Disorders (2014)
    Perminder S. Sachdev, Raj N. Kalaria et al. Alzheimer Disease & Associated Disorders
  5. Vascular cognitive impairment (2018)
    Wiesje M. van der Flier, Ingmar Skoog et al. Nature Reviews Disease Primers
  6. Spectral-Domain OCT Measurements in Alzheimer’s Disease (2018)
    Victor T.T. Chan, Zihan Sun et al. Ophthalmology
  7. Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment (2022)
    Vismitha Rajeev, David Y. Fann et al. Theranostics

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 77 standout
Sub-graph 1 of 19

Citing Papers

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 Standout
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
2024 Standout

Works of Christopher Chen being referenced

Lecanemab in Early Alzheimer’s Disease
2022 Standout

Author Peers

Author Last Decade Papers Cites
Christopher Chen 4835 3956 4097 5475 606 22.0k
Geert Jan Biessels 5340 6196 4178 7081 429 25.2k
Charles DeCarli 9216 3845 2702 6420 431 23.1k
M. Arfan Ikram 6210 3291 5403 6209 817 32.5k
Sudha Seshadri 6690 3519 4235 7338 463 29.7k
Mark A. van Buchem 5218 3213 3324 3720 469 24.0k
Lars‐Olof Wahlund 9208 4393 2273 8094 437 23.9k
Raj N. Kalaria 4624 7389 2499 6103 269 19.1k
John C. van Swieten 4817 4172 4440 6971 265 23.2k
Martin Dichgans 4824 6175 5724 3190 416 27.2k
Cornelia M. van Duijn 4602 3200 3072 9417 669 39.4k

All Works

Loading papers...

Rankless by CCL
2026